Document is current

Article History

First Online: 25 April 2019

Compliance with Ethical Standards

:

: Neither author declares any conflicts of interest relevant to this manuscript. However, Dr. Bakris is a principal investigator—FIDELIO trial (Bayer); Steering Committee CREDENCE (Janssen); CALM-2 (Vascular Dynamics). He is a consultant—Merck; Novo Nordisk; KBP; Relypsa. These are largely focused on diabetic nephropathy and not guidelines.

: This article does not contain any studies with human or animal subjects performed by any of the authors.